Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Immunol. 2016 Jan 6;196(3):1044–1059. doi: 10.4049/jimmunol.1501962

Figure 7. Administration of α-GalCer induces a maternal systemic pro-inflammatory response yet rosiglitazone drives a maternal systemic anti-inflammatory response.

Figure 7

Pregnant mice were i.v. injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. Serum concentrations of pro-inflammatory (A) and anti-inflammatory (B) cytokines/chemokines were determined 24 h after the initial injection. Data are from individual dams, n=8–9 each.